Sysmex (SSMXY) to Release Earnings on Wednesday

Sysmex (OTCMKTS:SSMXY) is expected to be announcing its resultson Wednesday, August 5th. Analysts expect Sysmex to announce earnings of $0.07 per share and revenue of $739.4560 million for the quarter. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The firm had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. On average, analysts expect Sysmex to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sysmex Price Performance

Shares of SSMXY stock traded up $0.20 during trading hours on Wednesday, hitting $10.15. The stock had a trading volume of 554 shares, compared to its average volume of 224,973. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of 26.72 and a beta of 1.07. Sysmex has a one year low of $8.01 and a one year high of $16.90. The stock’s 50-day moving average price is $9.13 and its two-hundred day moving average price is $9.05.

Analysts Set New Price Targets

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.